A minimal physiologically‐based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti‐ LAG ‐3 monoclonal antibody
CPT: Pharmacometrics & Systems Pharmacology · 2025
DOI: 10.1002/psp4.13285 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Robin Michelet und 8 weiteren Autor:innen. Beteiligte Einrichtung: qPharmetra LLC, Berlin, Germany. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Models, Biological. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boehringer Ingelheim Pharma GmbH & Co. KG.
Abstract (Originalsprache)
In oncology drug development, measuring drug concentrations at the tumor site and at the targeted receptor remains an ongoing challenge. Positron emission tomography (PET)‐imaging is a promising noninvasive method to quantify intratumor exposure of a radiolabeled drug (biodistribution data) and target saturation by treatment doses in vivo. Here, we present the development and application of a minimal physiologically‐based pharmacokinetic (mPBPK) modeling approach to integrate biodistribution data in a quantitative platform to characterize and predict intratumor exposure and receptor occupancy (RO) of BI 754111, an IgG‐based anti‐lymphocyte‐activation gene 3 (LAG‐3) monoclonal antibody (mAb). Specifically, calibration and qualification of the predictions were performed using 89 Zr‐labeled BI 754111 biodistribution data, that is, PET‐derived intratumor drug concentration data, tumor‐to‐plasma ratios, and data from Patlak analyses. The model predictions were refined iteratively by the inclusion of additional biological processes into the model structure and the use of sensitivity analyses to assess the impact of model assumptions and parameter uncertainty on the predictions and model robustness. The developed mPBPK model allowed an adequate description of observed tumor radioactivity concentrations and tumor‐to‐plasma ratios leading to subsequent adequate prediction of LAG‐3 RO at different dose levels. In the future, the developed model could be used as a platform for the prediction and analysis of biodistribution data for other mAbs and may ultimately support dose optimization by identifying dosages resulting in saturated RO.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- qPharmetra LLC, Berlin, Germany.
- qPharmetra LLC, Stockholm, Sweden.
- Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
- Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
- Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands.
- Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.
ORCID-Profile: Robin Michelet, Iris H C Miedema, David Busse
Förderung
- Boehringer Ingelheim Pharma GmbH & Co. KG
Zitieren
APA
Michelet, R., Petersson, K., Huisman, M. C., Menke-van der Houven van Oordt, C. W., Miedema, I. H. C., Thiele, A., Montaseri, G., Pérez-Pitarch, A., & Busse, D. (2025). A minimal physiologically‐based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti‐ LAG ‐3 monoclonal antibody. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13285
Vancouver
Michelet R, Petersson K, Huisman MC, Menke-van der Houven van Oordt CW, Miedema IHC, Thiele A, et al. A minimal physiologically‐based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti‐ LAG ‐3 monoclonal antibody. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.13285
BibTeX
@article{Michelet2025,
author = {Michelet, Robin and Petersson, Klas and Huisman, Marc C and Menke-van der Houven van Oordt, C Willemien and Miedema, Iris H C and Thiele, Andrea and Montaseri, Ghazal and Pérez-Pitarch, Alejandro and Busse, David},
title = {A minimal physiologically‐based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti‐ LAG ‐3 monoclonal antibody},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2025},
doi = {10.1002/psp4.13285}
}
EUVIMED